Ascendis Pharma Sets 2026 Milestones and Unveils $120 Million Share Buyback

Ascendis Pharma ( (ASND) ) has shared an announcement.

On January 9, 2026, Ascendis Pharma outlined a 2026 business and strategic roadmap highlighting strong commercial uptake of YORVIPATH, which had more than 5,300 unique U.S. patient enrollments and broad international availability by year-end 2025, with further launches planned in at least 10 additional countries by the end of 2026 and continued label-expansion trials. The company noted that SKYTROFA secured its first U.S. label expansion in July 2025 for adult growth hormone deficiency and that a Phase 3 basket trial is underway for additional growth-related indications, while its TransCon CNP program is advancing toward key regulatory decisions in the U.S. and Europe for pediatric achondroplasia and into Phase 3 combination studies with TransCon hGH following positive Phase 2 COACH Trial data reported on January 8, 2026. Ascendis also flagged upcoming 2026 data readouts for its TransCon IL-2 β/γ oncology program, progress of partnered assets with Novo Nordisk in obesity and metabolic disease and with Eyconis in ophthalmology, and regulatory momentum in Greater China and Japan via VISEN Pharmaceuticals and Teijin Limited, including an expected early-2026 approval in China for pediatric growth hormone deficiency and an existing Japanese approval of YORVIPATH in August 2025. In a capital allocation move that may support shareholder value and signal confidence in its outlook, the board authorized a $120 million share repurchase program, giving the company flexibility to buy back stock in the open market or through other permitted methods depending on market conditions and other factors.

The most recent analyst rating on (ASND) stock is a Buy with a $246.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.

Spark’s Take on ASND Stock

According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.

Ascendis Pharma’s overall stock score is primarily influenced by its financial performance challenges, including high leverage and negative cash flows. While the earnings call provided positive insights into revenue growth and regulatory progress, the stock’s valuation remains unattractive due to ongoing losses. Technical indicators suggest a lack of strong momentum, further impacting the score.

To see Spark’s full report on ASND stock, click here.

More about Ascendis Pharma

Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing and commercializing TransCon technology-based therapies, primarily in endocrinology, oncology, and rare diseases. Its key marketed products include TransCon PTH (YORVIPATH) for hypoparathyroidism and TransCon hGH (SKYTROFA) for growth hormone deficiency, while its pipeline features TransCon CNP for pediatric achondroplasia and TransCon IL-2 β/γ for oncology, complemented by multiple regional and global partnerships in metabolic, ophthalmology, and endocrinology markets.

Average Trading Volume: 579,454

Technical Sentiment Signal: Buy

Current Market Cap: $12.75B

See more insights into ASND stock on TipRanks’ Stock Analysis page.